These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26228373)

  • 1. Hepatitis C position statement: Taking a stand and standing by it.
    Sanai FM; Alghamdi AS; Alghamdi MY
    Saudi J Gastroenterol; 2015; 21(4):262-3. PubMed ID: 26228373
    [No Abstract]   [Full Text] [Related]  

  • 2. SASLT position statement on the direct-acting antiviral agents for the treatment of hepatitis C virus infection.
    Alghamdi AS; Alqutub A; Abaalkhail F; Sanai FM; Alghamdi H; Altraif I; Alswat KA; Alghamdi MY; Babatin MA; Alfaleh FZ
    Saudi J Gastroenterol; 2015; 21(2):60-3. PubMed ID: 25843190
    [No Abstract]   [Full Text] [Related]  

  • 3. Ribavirin-free treatment may soon be a reality.
    Al-Judaibi B
    Saudi J Gastroenterol; 2015; 21(4):260-1. PubMed ID: 26228372
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatitis B and C virus resistance to antiviral therapies--EASL-AASLD-APASL-ALEH-IASL conference.
    Buti M
    IDrugs; 2008 Apr; 11(4):239-41. PubMed ID: 18379952
    [No Abstract]   [Full Text] [Related]  

  • 5. Ribavirin: is it a mutagen for hepatitis C virus?
    Perelson AS; Layden TJ
    Gastroenterology; 2007 May; 132(5):2050-2. PubMed ID: 17484896
    [No Abstract]   [Full Text] [Related]  

  • 6. PSG consensus statement on management of hepatitis C virus infection--2003.
    Hamid S; Umar M; Alam A; Siddiqui A; Qureshi H; Butt J;
    J Pak Med Assoc; 2004 Mar; 54(3):146-50. PubMed ID: 15129876
    [No Abstract]   [Full Text] [Related]  

  • 7. Interferon/pegylated interferon and ribavirin in HCV-associated kidney disease with or without cryoglobulinemia.
    Bruchfeld A; Lindahl K; Stahle L; Schvarcz R
    J Hepatol; 2006 Feb; 44(2):432-3; author reply 433. PubMed ID: 16338023
    [No Abstract]   [Full Text] [Related]  

  • 8. Analysis of sequence configurations of the PKR-interacting HCV proteins from plasma and PBMC as predictors of response to interferon-alpha and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Bull L; Martinez L; Reynoso R; Salomon H; Arduino R; Barnett B; Quarleri J
    Intervirology; 2008; 51(4):261-4. PubMed ID: 18824873
    [No Abstract]   [Full Text] [Related]  

  • 9. [Argentine consensus on hepatitis C 2013].
    Reggiardo MV; Tanno F; Mendizabal M; Galdame O
    Acta Gastroenterol Latinoam; 2014 Jun; 44(2):154-73. PubMed ID: 25199310
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of acute hepatitis C-how to explain the differences?
    Wedemeyer H; Cornberg M; Wiegand J; Jäckel E; Manns MP
    Gastroenterology; 2006 Aug; 131(2):682-3; author reply 683-4. PubMed ID: 16890627
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of hepatitis C. Different modalities based on viral genotype].
    Pariente A
    Rev Prat; 2003 Jun; 53(11):1175-6. PubMed ID: 15185639
    [No Abstract]   [Full Text] [Related]  

  • 12. HCV findings presented at EASL: long-term follow-up and the criteria of a cure.
    Lang L
    Gastroenterology; 2007 Jun; 132(7):2282-3. PubMed ID: 17570197
    [No Abstract]   [Full Text] [Related]  

  • 13. Mechanism of interferon resistance in hepatitis C.
    Gretch D
    Lancet; 2001 Nov; 358(9294):1662-4. PubMed ID: 11728538
    [No Abstract]   [Full Text] [Related]  

  • 14. Virology of hepatitis B and C viruses and antiviral targets.
    Pawlotsky JM
    J Hepatol; 2006; 44(1 Suppl):S10-3. PubMed ID: 16338022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current and future therapies for hepatitis C virus infection.
    Ozaras R; Yemisen M; Balkan İİ
    N Engl J Med; 2013 Aug; 369(7):679. PubMed ID: 23944319
    [No Abstract]   [Full Text] [Related]  

  • 16. Tailoring antiviral therapy in hepatitis C.
    Davis GL
    Hepatology; 2006 May; 43(5):909-11. PubMed ID: 16628667
    [No Abstract]   [Full Text] [Related]  

  • 17. The importance of rapid viral suppression in the era of directly acting antiviral therapy for hepatitis C virus.
    Jenkins ET; Jensen DM
    Infect Dis Clin North Am; 2012 Dec; 26(4):879-91. PubMed ID: 23083821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of acute hepatitis C with interferon alfa-2b.
    Patel R; Germer JJ
    N Engl J Med; 2002 Apr; 346(14):1091-2. PubMed ID: 11932480
    [No Abstract]   [Full Text] [Related]  

  • 19. Hepatitis C treatment gets into a new gear.
    Khokhar N
    J Coll Physicians Surg Pak; 2014 Dec; 24(12):879-81. PubMed ID: 25523720
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment choice of the antiviral agent for the hepatitis C].
    Karino Y
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():269-73. PubMed ID: 26845943
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.